

An Approach to Graphically Evaluate Steatosis in Non-Alcoholic Fatty Liver Disease

M. Nystrom¹, C. Y-F. Lo¹, P. W. Chu¹, S. M. Noworolski^{1,2}, and A. Qayyum¹

¹Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, United States, ²Graduate Group in Bioengineering, San Francisco & Berkeley, University of California, San Francisco

Introduction Hepatic steatosis affects 30% of the adult population in the western world [1] and is characteristic of many chronic liver diseases. Currently, the gold-standard to determine the severity of liver disease, including steatosis, is liver biopsy, which is an invasive procedure prone to sampling error due to small specimen size (less than 1/50,000th of the liver) [2]. A major pitfall in the assessment of steatosis is its heterogeneous distribution. While MRI provides a non-invasive alternative to liver biopsy for quantification of steatosis with opposed-phase T1-weighted GRE imaging [3], the method depends on manually drawn regions of interest and cumbersome mathematical equations. Furthermore, quantification is affected by placement of regions of interest and could be misleading in the assessment of disease progression. The aim of this study was to develop a color mapping technique based on liver signal intensity loss on in- and out-of-phase images to readily and accurately assess the steatosis grade and heterogeneity.

Methods 38 patients diagnosed with non-alcoholic fatty liver disease (NAFLD, 20 men and 18 women; mean age 44 years, range 11-73) and 20 healthy volunteers (10 men and 10 women; mean age 31 years, range 22-48) underwent MRI using a 1.5T GE scanner. Coronal breath-hold T1-weighted dual fast gradient echo sequences were acquired of the abdomen (TR/TE 90/4.2 and 2.1 ms; flip angle 75°; slice/gap 8/1 mm; matrix 256x128-192, NEX 1). Patients underwent a liver biopsy for steatosis grading within 3 months of the MRI scan (average 23.7 days, median 12 days, range 0-83 days). The number of subjects with steatosis grades 0, 1, 2 and 3 were 5, 7, 11 and 15, respectively.




Figure 1. Used recursive partitioning to find cut-off points of % SI Loss to signify steatosis grades 0-3.

% SI loss cut-off points	Steatosis grade
<7	0
7-31	1
32-37	2
≥38	3

Table 1 - %SI Loss
Cut-off points for Steatosis Grades.




Figure 3. Coronal T1 images with color representation of steatosis grade. (a) is an example of steatosis grade 0, (b) is steatosis grade 1, (c) is steatosis grade 2, and (d) is steatosis grade 3.




Figure 4 - Example of liver heterogeneity. Although the histopathological result defined the liver as grade 2, the visible grades range from 0 - 3.

Discussion We found a strong agreement between imaging and histopathological results and between the steatosis severity and heterogeneity assessments of the two readers. Since liver biopsy samples a very small portion of the liver and steatosis is frequently a heterogeneous process, such a technique is unlikely to represent a dependable gold standard of the state of the entire liver. The small histopathological sampling of such a heterogeneous disease process may have negatively contributed to the correlation between observed SI loss and that of histopathology. One of the limitations of this study is the narrow range of percent SI loss signifying grade 2 steatosis. This also could have caused a reduction in the ability to correctly grade liver steatosis with SI loss. A second limitation is the lack of T2* correction, however the subjects studied were not considered to be at risk for liver iron deposition. Regardless, results are very promising. MRI may still be a more realistic determinant of disease extent. Further investigation into this technique could offer a rapid, easy to interpret, noninvasive, and more comprehensive approach to accurate steatosis severity and heterogeneity assessment than a single liver biopsy.

References 1. D Priess, N Sattar. Clin Sci 2008; 115(5): 141-50. 2. S R. Mehta, et al. W. J. of Gastroenterology. 2008 14(22): 3476-3483
3. M Bahl, et al. Radiology. 2008 249(1): 160-6. 4. A Qayyum, et al. Radiology. 2005. 237(2): 507-11.

Acknowledgements NIH R01 DK074718-01A1